Boston Scientific Corp. (NYSE:BSX) was granted U.S. Food & Drug Administration approval for leads designed for use in its Precision Plus spinal cord stimulator system. The Linear 3-4 and Linear 3-6 leads, when combined with the recently approved W4 and D4 lead splitters, provide physicians with the broadest range of percutaneous lead configurations in the […]
Boston Scientific Corp. (NYSE:BSX) launched two spinal cord stimulation lead splitters for use with its Precision Plus spinal cord stimulator system. The new design enables multi-site placement of up to four spinal cord leads designed to deliver electrical pulses that mask back pain signals on their way to the brain. Boston Scientific said in a press […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Boston Scientific Corp. (NYSE:BSX) enrolled the first patient in its Evidence clinical trial comparing spinal cord stimulation with second operations for patients whose first back surgeries failed. The Natick, Mass.-based medical device giant said the 132-patient trial will compare its Precision Plus spinal cord stimulator system with revision surgery to treat patients with failed back […]